Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Gynecol Oncol. 2018 May 5;150(1):9–13. doi: 10.1016/j.ygyno.2018.04.572

Table 3.

Efficacy Endpoints

Efficacy Endpoint Cabozantinib
N %
Best Objective Tumor Response
  Stable Disease (≥6 weeks) 7 54
  Disease progression 4 31
  Not evaluable 2 15
Complete or Partial Response 0  0

Progression-Free Survival
  ≥6 months 3 23
  Median (95% CI), months 3.6 (1.8, 7.9)

Overall Survival
  Median (95% CI), months 8.1 (2.7, >20.1)